Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study evaluated the incidence of imatinib-associated skin rash, the interventional out- comes of severe rash, and impact of severe rash on the outcomes of imatinib treatment in gastrointestinal stromal tumor (GIST) patients. Materials and Methods A total of 620 patients were administered adjuvant or palliative imatinib for GIST at Asan Medical Center between January 2000 and July 2012. This analysis focused on a group of 42 patients who developed a severe rash requiring major interventions, defined as dose interruption or reduction of imatinib or systemic steroid use. Results Of the 620 patients treated with imatinib, 148 patients (23.9%) developed an imatinib- associated skin rash; 42 patients (6.8%) developed a severe rash requiring major interven- tion. Of these, 28 patients (66.8%) successfully continued imatinib with interventions. Serial blood eosinophil levels during imatinib treatment were associated with skin rash and sever- ity. A significant association was observed between successful intervention and blood eosinophil level at the time of intervention initiation. In metastatic settings, patients with severe rash requiring major interventions tended to show poorer progression-free survival than patients who did not require major intervention and patients with no rash, although this finding was not statistically significant (p=0.326). Conclusion By aggressive treatment of severe rash through modification of imatinib dose or use of sys- temic steroid, the majority of patients can continue on imatinib. In particular, imatinib dose intensity can be maintained with use of systemic steroid. Measuring the blood eosinophil levels may be helpful in guiding the management plan for skin rash regarding the intensity and duration of interventions.
Abstract
Purpose This study evaluated the incidence of imatinib-associated skin rash, the interventional out- comes of severe rash, and impact of severe rash on the outcomes of imatinib treatment in gastrointestinal stromal tumor (GIST) patients. Materials and Methods A total of 620 patients were administered adjuvant or palliative imatinib for GIST at Asan Medical Center between January 2000 and July 2012. This analysis focused on a group of 42 patients who developed a severe rash requiring major interventions, defined as dose interruption or reduction of imatinib or systemic steroid use. Results Of the 620 patients treated with imatinib, 148 patients (23.9%) developed an imatinib- associated skin rash; 42 patients (6.8%) developed a severe rash requiring major interven- tion. Of these, 28 patients (66.8%) successfully continued imatinib with interventions. Serial blood eosinophil levels during imatinib treatment were associated with skin rash and sever- ity. A significant association was observed between successful intervention and blood eosinophil level at the time of intervention initiation. In metastatic settings, patients with severe rash requiring major interventions tended to show poorer progression-free survival than patients who did not require major intervention and patients with no rash, although this finding was not statistically significant (p=0.326). Conclusion By aggressive treatment of severe rash through modification of imatinib dose or use of sys- temic steroid, the majority of patients can continue on imatinib. In particular, imatinib dose intensity can be maintained with use of systemic steroid. Measuring the blood eosinophil levels may be helpful in guiding the management plan for skin rash regarding the intensity and duration of interventions.
참고문헌 (16)
- Demetri GD, "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors", N Engl J Med, 347, pp.472~480 (2002)
- Verweij J, "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial", Lancet, 364, pp.1127~1134 (2004)
- Blanke CD, "Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT", J Clin Oncol, 26, pp.620~625 (2008)
- Dematteo RP, "Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebo-controlled trial", Lancet, 373, pp.1097~1104 (2009)
- Joensuu H, "One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trial", JAMA, 307, pp.1265~1272 (2012)
- Demetri GD, "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial", Lancet, 368, pp.1329~1338 (2006)
- Demetri GD, "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.295~302 (2013)
- Kang YK, "Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3trial", Lancet Oncol, 14, pp.1175~1182 (2013)
- ESMO, "European Sarcoma Network Working Group", Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2012, pp.23(Suppl 7), 49~55
- 강윤구, "Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea", Cancer Research and Treatment, 44(2), pp.85~96 (2012), 대한암학회[DOI]
- Le Cesne A, "Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment : an open-label multicentre randomised phase 3 trial", Lancet Oncol, 11, pp.942~949 (2010)
- Demetri GD, "Imatinib plasma levels are correlated with clinical benefit in patients with unresectable", metastatic gastrointestinal stromal tumors, 2009, pp.27, 3141~3147
- Heinrich MC, "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors", J Clin Oncol, 24, pp.4764~4774 (2006)
- Longley BJ, "SCF-KIT pathway in human epidermal melanocyte homeostasis", J Invest Dermatol, 113, pp.139~140 (1999)
- Park HJ, "Immunohistochemical characterization of cutaneous drug eruptions by STI571", J Dermatol Sci, 38, pp.9~15 (2005)
- Fulkerson PC, "Targeting eosinophils in allergy, inflammation and beyond", Nat Rev Drug Discov, 12, pp.117~129 (2013)